Perspective Therapeutics Files 8-K

Ticker: CATX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 728387

Sentiment: neutral

Topics: financial-condition, company-update

TL;DR

Perspective Therapeutics filed an 8-K on Jan 13, 2025, updating financials and events. Formerly Isoray.

AI Summary

Perspective Therapeutics, Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition, as well as other events. The filing also includes financial statements and exhibits. The company was formerly known as Isoray, Inc. and IsoRay, Inc. before changing its name in 2018 and 2005 respectively.

Why It Matters

This 8-K filing provides an update on the company's financial status and significant events, which is crucial for investors to assess its current performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on financial condition and other events, not indicating any immediate significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on the Registrant's Results of Operations and Financial Condition, as well as other events, and to include financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 13, 2025.

What were the previous names of Perspective Therapeutics, Inc.?

Perspective Therapeutics, Inc. was formerly known as Isoray, Inc. (name change effective December 31, 2018) and IsoRay, Inc. (name change effective August 5, 2005).

Where is Perspective Therapeutics, Inc. incorporated and what is its IRS Employer Identification No.?

Perspective Therapeutics, Inc. is incorporated in Delaware and its IRS Employer Identification No. is 41-1458152.

What is the business address and phone number for Perspective Therapeutics, Inc.?

The business address for Perspective Therapeutics, Inc. is 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE, WA 98121, and the business phone number is 206-676-0900.

Filing Stats: 619 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-01-13 08:36:16

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Perspective Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") announcing certain business updates and strategic priorities for the Company and disclosing certain estimated and projected financial information, including its estimated cash, cash equivalents and short-term investments as of December 31, 2024. The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2024. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2024. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein. Also on January 13, 2025, the Company posted an updated corporate presentation on its website at www.perspectivetherapeutics.com (the "Corporate Presentation"), which included the Company's estimated cash, cash equivalents and short-term investments as of December 31, 2024. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

01 Other Events

Item 8.01 Other Events. On January 13, 2025, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 hereto and is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 13, 2025 . 99.2 Corporate Presentation . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PERSPECTIVE THERAPEUTICS, INC. Date: January 13, 2025 By: /s/ Johan (Thijs) Spoor Johan (Thijs) Spoor Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing